Conversely, prostate‐specific membrane antigen (PSMA) targeted ligands with high affinity for cell surface PSMA over‐expressed in prostate cancer cells, tend to be antagonists and, thus, block the action of the cell surface antigen. The gene discussed is FOLH1; the disease is prostate cancer.